Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials

Stem Cell Reports(2026)10.1016/j.stemcr.2026.102854Source: DataRank Database

Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials is a research paper published in Stem Cell Reports (2026). On theSindex it has a DataRank of 0.208. It has been cited 3 times.

N/A

0.208DataRank · unranked

Scored on demand from live citation data

3 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 20.30)OA: goldTopics (51)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.208

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (17)

Dean A. Fergusson ORCID,Manoj Mathew Lalu ORCID,David W. Courtman,Saad Khan ORCID,Mohamad Sobh

Live enrichment

PubMed:41825447 PMC:PMC13083786 OpenAlex:https://openalex.org/W7135028841

Canadian Institutes of Health Research

Grant: 172654

Ontario Research Foundation

Grant: C-097-2425756-STEWART

Canadian Institutes of Health Research

Grant: unidentified

unidentified

Bundesministerium für Forschung, Technologie und Raumfahrt

Stem Cell Network

FWCI

20.30

Citation Percentile

1.0%

Citation Trend

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.stemcr.2026.102854

publisherhttps://doi.org/10.1016/j.stemcr.2026.102854

publisherhttps://api.elsevier.com/content/article/PII:S2213671126000652?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2213671126000652?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41825447

Fields of Study

Long-Term Effects of COVID-19COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research0303 health sciences03 medical and health sciencesHumansCOVID-19Respiratory Distress SyndromeFemaleSARS-CoV-2Mesenchymal Stem CellsMiddle AgedMesenchymal Stem Cell TransplantationMaleAdultAgedTreatment OutcomeUmbilical CordImmunotherapyQuality of LifeLymphopenia

MeSH Terms

COVID-19SARS-CoV-2AdultAgedFemaleHumansImmunotherapyLymphopeniaMaleMiddle AgedQuality of LifeRespiratory Distress SyndromeUmbilical CordTreatment OutcomeMesenchymal Stem Cell TransplantationMesenchymal Stem Cells

Keywords

Acute respiratory distressRandomized controlled trialImmunotherapyPhase (matter)Clinical trialPhases of clinical researchImmunomodulationCell therapyAcute respiratory distress syndromeMesenchymal Stem CellsLymphopeniaRandomized Clinical TrialCovid-19Sars-cov2

Sustainable Development Goals

SDG 0: Good health and well-being

Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials

FAIR Checklist

DataRank Breakdown

Authors (17)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)